B
Bio Green Med Solution, Inc.
BGMSPCIK 0001130166OTCNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-3.00M
Total Assets
$8.19M
Equity
$6.84M
Shares Out
5.52M
Op. Cash Flow
$-4.77M
Business
Bio Green Med Solution, Inc. is a clinical-stage biopharmaceutical company developing cancer medicines based on cell cycle, epigenetics and mitosis biology. Its main product candidate is plogosertib (plogo), an oral, selective PLK1 inhibitor being evaluated in Phase 1/2 trials for multiple solid tumors and lymphomas. The company’s organization is centered on a mitosis regulation program and a streamlined clinical development pipeline focused on plogo, with retained worldwide commercialization rights. It conducts clinical trials and regulatory activities in the United States, Europe and other international jurisdictions and relies on third-party manufacturers and selective partnerships for development and commercialization.
Summary from filing dated 2025-04-02
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 747,000 | 43,000 | 420,000 | 0 | 0 | |
| Cost of sales | 609,000 | — | — | — | — | |
| Research and development | 848,000 | 7 | 19 | 20 | 15 | |
| General and administrative | 8 | 5 | — | — | — | |
| Total operating expenses | 9 | 12 | 26 | 28 | — | |
| Operating loss | −8 | −12 | −25 | −28 | −23 | |
| Foreign exchange losses | 73,000 | −54,000 | −414,000 | 233,000 | 44,000 | |
| Interest income | 62,000 | 12,000 | — | — | — | |
| Gain on deconsolidation of former subsidiary | 5 | — | — | — | — | |
| Other income, net | 354,000 | 52,000 | 50,000 | 1 | — | |
| Total other income, net | 5 | 10,000 | −98,000 | 2 | 204,000 | |
| Loss before taxes | −3 | −12 | −26 | −26 | −23 | |
| Income tax benefit / (provision) | −7,000 | 782,000 | 3 | 5 | 4 | |
| Net loss | −3 | −11 | −23 | −21 | −19 | |
| Dividend on convertible exchangeable preferred shares | −61,000 | — | −201,000 | −201,000 | −201,000 | |
| Deemed dividend on warrant exchange | −11 | — | — | — | — | |
| Net loss applicable to common shareholders | −14 | −11 | — | — | — | |
| Net loss per share - basic (common shareholders) | −6.45 | −502.46 | −26.75 | −1.9 | −2.14 | |
| Net loss per share - diluted (common shareholders) | −6.45 | −502.46 | −26.75 | −27.24 | −2.14 | |
| Weighted average common shares outstanding - basic | 2 | 22,314 | — | 11 | 9 | |
| Weighted average common shares outstanding - diluted | 2 | 22,314 | — | 11 | 9 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-08-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | — | 3 | 3 | 18 | |
| Accounts receivable | 1 | — | — | — | — | |
| Inventory | 1 | — | — | — | — | |
| Prepaid expenses and other current assets | 110,000 | — | 537,000 | 4 | 6 | |
| Total current assets | 6 | — | 4 | 7 | 24 | |
| Property and equipment, net | 137,000 | — | 3,000 | 9,000 | 32,000 | |
| Right-of-use lease asset | 12,000 | — | 5,000 | 93,000 | 142,000 | |
| Goodwill | 2 | 1,570 | — | — | — | |
| Non-current assets | 210,000 | — | 412,000 | — | — | |
| Total assets | 8 | — | 4 | 9 | 28 | |
| Accounts payable | 617,000 | — | 5 | 4 | 3 | |
| Accrued and other current liabilities | 715,000 | — | 2 | 5 | 5 | |
| Total current liabilities | 1 | — | 6 | 8 | 8 | |
| Lease liability | 2,000 | — | — | 37,000 | 106,000 | |
| Other liabilities | 9,000 | — | — | — | — | |
| Total liabilities | 1 | — | 6 | 8 | 8 | |
| Common stock, $0.001 par value; 600,000,000 shares authorized at December 31, 2025 and 100,000,000 shares authorized at December 31, 2024; 5,400,320 shares issued and outstanding at December 31, 2025 and 36,913 shares issued and outstanding at December 31, 2024 | 5,000 | — | — | 1,000 | 1,000 | |
| Additional paid-in capital | 461 | — | 438 | 430 | 423 | |
| Accumulated other comprehensive loss | −39,000 | — | −891,000 | −908,000 | −1 | |
| Accumulated deficit | −454 | — | −439 | −428 | −406 | |
| Total stockholders equity (deficit) | 7 | — | −2 | 607,000 | 16 | |
| Total liabilities and stockholders equity (deficit) | 8 | — | 4 | 9 | 28 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 5,000 | 6,000 | 31,000 | 32,000 | 43,000 | |
| Gain on deconsolidation of subsidiary | 5 | — | — | — | — | |
| Stock-based compensation | 2 | 592,000 | 1 | 2 | 1 | |
| Changes in lease liability | 2,000 | −37,000 | −69,000 | 40,000 | 172,000 | |
| Accounts receivable, net | −1 | — | — | — | — | |
| Inventory | −1 | — | — | — | — | |
| Prepaid expenses and other assets | 4 | 4 | — | — | — | |
| Accounts payable, accrued and other current liabilities | −11 | −2 | 296,000 | 3 | 3 | |
| Net cash used in operating activities | −5 | −8 | −16 | −21 | −19 | |
| Purchase of property, plant and equipment | — | — | −6,000 | −7,000 | −27,000 | |
| Net cash used in investing activities | — | — | −6,000 | −7,000 | −27,000 | |
| Proceeds, net of issuance costs, from issuing common stock and pre-funded warrants, net | 6 | 6 | 1 | — | — | |
| Payment made under the Warrant Exchange Amendment | −1 | — | — | — | — | |
| Proceeds from the exercise of stock options and warrants, net of issuance costs | — | 2 | — | — | — | |
| Payment of preferred stock dividend | −61,000 | — | −201,000 | −201,000 | −201,000 | |
| Net cash provided by in financing activities | 5 | 8 | 848,000 | 3 | 22 | |
| Effect of exchange rate changes on cash and cash equivalents | −126,000 | −73,000 | 303,000 | −378,000 | −17,000 | |
| Net increase (decrease) in cash and cash equivalents | 368,000 | −241,000 | −15 | −18 | 3 | |
| Issuance of shares in acquisition of Fitters Sdn. Bhd. | 4 | — | — | — | — | |
| Warrant Exchange | 11 | — | — | — | — | |
| Interest | 68,000 | 96,000 | 266,000 | 211,000 | 17,000 | |
| Research & development tax credits | — | 4 | 5 | 3 | 1 | |
| Interest | 7,000 | — | — | — | — | |
| Taxes | 18,000 | 2,000 | 2,000 | 2,000 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro